Adenocarcinoma of the Gastroesophageal Junction or Gastric
Showing 26 - 50 of 7,448
Advanced Gastric Adenocarcinoma Trial in Henan (camrelizumab)
Recruiting
- Advanced Gastric Adenocarcinoma
-
Henan, ChinaHenan Tumor Hospital
Oct 13, 2022
Patterns in HER2-Positive Locally Advanced or Metastatic Gastric
Not yet recruiting
- Gastric Cancer
- (no location specified)
Feb 1, 2023
Metastatic Gastric Cancer Trial in Zhengzhou (fruquintinib+toripalimab + SOX)
Recruiting
- Metastatic Gastric Cancer
- fruquintinib＋toripalimab + SOX
-
Zhengzhou, Henan, ChinaThe First Affiliated Hospital of Zhengzhou University
Aug 17, 2022
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial (pembrolizumab, paclitaxel)
Completed
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- pembrolizumab
- paclitaxel
- (no location specified)
May 12, 2022
Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy, Immunotherapy Trial (Envafolimab)
Not yet recruiting
- Gastric/Gastroesophageal Junction Adenocarcinoma
- +2 more
- (no location specified)
May 18, 2022
HER2-positive Locally Advanced Resectable Gastric Cancer Trial (KN026, KN046, XELOX)
Not yet recruiting
- HER2-positive Locally Advanced Resectable Gastric Cancer
- KN026
- +2 more
- (no location specified)
Sep 3, 2023
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Tucson (Tadalafil 20 MG)
Not yet recruiting
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Tadalafil 20 MG
-
Tucson, ArizonaArizona Cancer Center at UMC North/University Medical Center
Feb 1, 2023
Immune Suppression, Gastric Cancer Trial in Hangzhou (nivolumab combined with SOX)
Recruiting
- Immune Suppression
- Gastric Cancer
- nivolumab combined with SOX
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Feb 11, 2023
Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma Trial in United States
Recruiting
- Advanced Colorectal Carcinoma
- +42 more
- Elimusertib
- +3 more
-
Duarte, California
- +9 more
Jan 21, 2023
Stomach Tumors, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Atezolizumab, Tiragolumab, Oxaliplatin)
Active, not recruiting
- Stomach Neoplasms
- +2 more
- Atezolizumab
- +3 more
-
Beijing, China
- +10 more
Dec 21, 2022
Gastric Cancer, Gastroesophageal-junction Cancer Trial (IBI315, Oxaliplatin, Capecitabine)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal-junction Cancer
- IBI315
- +5 more
- (no location specified)
Nov 2, 2022
Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage I
Recruiting
- Clinical Stage 0 Gastric Cancer AJCC v8
- +27 more
- Fluorouracil
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jul 5, 2022
PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer Trial in Changchun (Drug: Toripalimab,
Recruiting
- PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer
- Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)
-
Changchun, Ji Lin, ChinaFirst Hospital of Jilin University
Jul 18, 2022
Gastric Cancer Trial in China (Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab)
Recruiting
- Gastric Cancer
- Experimental dose: modified XELOX + sintilimab
- Standard dose: standard XELOX + sintilimab
-
Guangzhou, Guangdong, China
- +9 more
Jun 23, 2023
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage
Recruiting
- Clinical Stage III Gastric Cancer AJCC v8
- +30 more
- Paclitaxel
- +3 more
-
Scottsdale, Arizona
- +11 more
Apr 4, 2022
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Multiple Locations
Recruiting
- Esophageal Squamous Cell Carcinoma
- +3 more
- Routine care as per site standard
-
Multiple Locations, GermanyMultiple sites, Gemany
Jun 3, 2022
Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer Trial (TST001, CapOx or mFOLFOX6 and NIVO or (Substudy)
Not yet recruiting
- Gastric Cancer
- +2 more
- TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
- Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
- (no location specified)
Oct 16, 2023
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma Trial in Kashiwa (Regorafenib,
Not yet recruiting
- Gastric Adenocarcinoma
- +2 more
- Regorafenib
- +3 more
-
Kashiwa, Chiba, JapanNational Cancer Center Hospital East
May 23, 2022
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction
Not yet recruiting
- Clinical Stage I Gastric Cancer AJCC v8
- +9 more
- Atezolizumab
- +12 more
- (no location specified)
Apr 26, 2023
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Jinan, Qingdao, Yantai (Serplulimab, Lenvatinib,
Not yet recruiting
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Serplulimab
- +2 more
-
Jinan, Shandong, China
- +5 more
Oct 16, 2022
Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Gastric Cancer AJCC v8
Recruiting
- Advanced Gastric Adenocarcinoma
- +32 more
- Lenvatinib
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Mar 2, 2022
Gastric Cancer Trial
Completed
- Gastric Cancer
- (no location specified)
Dec 20, 2022
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Beijing (CS1001 mAb, CS1001 , Oxaliplatin)
Active, not recruiting
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- CS1001 monoclonal antibody
- +3 more
-
Beijing, ChinaBeijing Cancer Hospital
Sep 27, 2022